Physicians and Researchers Present at the 2019 American Society of Clinical Oncology (ASCO) Meeting in Chicago

UPMC Hillman Cancer Center and University of Pittsburgh physicians and researchers will be well-represented at the 2019 American Society of Clinical Oncology (ASCO) annual meeting in Chicago May 31 – June 4.  Faculty research will be featured in both oral presentations and poster sessions.

Saturday, June 1

Educational Session – 8 to 9:15 a.m.

The Management and Prevention of Anal Squamous Cell Carcinoma

Surveillance and the Management of Anal Intraepithelial Neoplasia in the HIV and Non-HIV Patient

Ian McGowan, MD, PhD, FRCP

Poster Sessions – 8 to 11 a.m.

Poster Board: #444, Abstract 10062

Morbidity and mortality in a national cohort of pediatric patients with hemophagocytic lymphohistiocytosis.

Stephen William Allen, MD

Interactive Case-Based Sessions – 4:45 – 5:45 p.m.

Many Challenges, Many Opportunities: Cancer Prevention in Patients With Multiple Risk Factors

Assessment and Management of Germline Mutations Predisposing to Breast Cancer

Phuong L. Mai, MD, MS

Poster Discussion Session – 3 to 4:30 p.m.

Poster Board: #338 • Abstract 11015

Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts.

Melissa Amber Burgess, MD

Poster Discussion Session – 4:30 to 6 p.m.

Health Services Research, Clinical Informatics, and Quality of Care

Poster Board: #210 • Abstract 6519

Quantification of the financial burden of antineoplastic agent price increases.

Michail Alevizakos, MD

Sunday, June 2

Education Session – 9:45 to 11 a.m.

Wanna Get Away? Continuous Treatments Versus Treatment Holidays in Gynecologic Cancer

Changing the Perspective for "Successful" Maintenance Therapy

Ronald J. Buckanovich, MD

Approaches to High-Risk Resected Stage II and III Melanoma

Stage II Melanoma: What Patients Are Appropriate for Adjuvant Therapy?

Jason J. Luke, MD, FACP

Poster Discussion Session – 11:15 a.m. to 12:15 p.m.

Breast Cancer—Metastatic

Poster Board: #94 • Abstract 1013

Phase II COLET study: Atezolizumab (A) + cobimetinib (C) + paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negative breast cancer (mTNBC).

Adam Brufsky, MD, PhD

Monday, June 3

Education Session – 8 to 9:15 a.m.

Management of Uncommon and Rare Breast Cancers

Natural History and Pathology of Rare Breast Cancer Subtypes

Peter C. Lucas, MD, PhD

Poster Session – 8 to 11 a.m.

Gastrointestinal (Colorectal) Cancer

Poster Board: #68 • Abstract 3576

High incidence of advanced stage cancer and prolonged rectal bleeding history before diagnosis in young-onset patients with colorectal cancer.

Gurprataap Singh Sandhu, MBBS

Oral Abstract Session – 8 to 11 a.m.

Genitourinary (Nonprostate) Cancer

Abstract 4502: Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metastasectomy: A trial of the ECOG-ACRIN cancer research group (E2810).

Leonard Joseph Appleman, MD, PhD

Poster Session – 1:15 – 4:15 p.m.

Melanoma/Skin Cancers

Poster Board: #142 • Abstract 9571

Association of baseline neutrophil-to-lymphocyte ratio (NLR) with response and survival in advanced melanoma (MEL) receiving PD-1 inhibitors.

Amit Hemadri, MD

Poster Board: #143 • Abstract 9572

Association of medication (Med) and antibiotic (Abx) use with response and survival in advanced melanoma (MEL) receiving PD-1 inhibitors.

Amit Hemadri, MD

Poster Board: #150 • Abstract 9579

Association of baseline body mass index (BMI) with response and survival in patients (Pts) with advanced melanoma (MEL) receiving PD-1 inhibitors.

Amit Hemadri, MD

Poster Board: #157 • Abstract 9586

A phase I study of neoadjuvant combination immunotherapy in locally/regionally advanced melanoma.

Yana Najjar, MD

Cancer Prevention, Hereditary Genetics, and Epidemiology

Poster Board: #64 • Abstract 1570

Sex-specific mortality trends in adolescents and young adults with cancer from 2007 to 2016.

Allison Close, MD

Poster Discussion Session – 4:30 to 6 p.m.

Melanoma/Skin Cancers

Peripheral Blood and Tumor Microenvironment Considerations for Immunotherapy

Jason J. Luke, MD, FACP

Discussing Abstract(s): 9515, 9516, 9517

Symptoms and Survivorship

Poster Board: #291 • Abstract 11599

Interim analyses of the efficacy of a collaborative care intervention for patients diagnosed with comorbid cancer and depression.

Jennifer Lynne Steel, PhD

Cocktail Reception